Edition:
United States

Surmodics Inc (SRDX.OQ)

SRDX.OQ on NASDAQ Stock Exchange Global Select Market

23.50USD
4:00pm EDT
Change (% chg)

$-1.30 (-5.24%)
Prev Close
$24.80
Open
$23.70
Day's High
$24.00
Day's Low
$23.45
Volume
16,125
Avg. Vol
13,674
52-wk High
$30.70
52-wk Low
$19.88

Latest Key Developments (Source: Significant Developments)

Surmodics Q2 non-gaap EPS $0.05
7:30am EDT 

April 27 (Reuters) - Surmodics Inc :Surmodics reports second quarter fiscal 2017 results, updates fiscal 2017 financial guidance.Q2 gaap earnings per share $0.04.Sees fy 2017 revenue $65 million to $68 million.Q2 revenue rose 5 percent to $17.5 million.Sees fy 2017 non-gaap earnings per share $0.15 to $0.25.Sees fy 2017 loss per share $0.02 to $+0.08.Q2 non-gaap earnings per share $0.05.Surmodics inc says narrows financial outlook for fiscal 2017.Surmodics inc says medical device revenue was $12.7 million in q2 of fiscal 2017, an increase of 9.7% compared to year-ago period.  Full Article

Surmodics reports Q1 non-GAAP earnings per share $0.19
Thursday, 2 Feb 2017 07:30am EST 

Surmodics Inc : Surmodics reports first quarter fiscal 2017 results . Surmodics reports first quarter fiscal 2017 results . Surmodics inc - raises revenue and eps guidance . Q1 revenue $17.8 million versus I/B/E/S view $15.8 million . Q1 non-GAAP earnings per share $0.19 . Surmodics Inc says remain on track to continue clinical evaluation of our surveil drug-coated balloon . Surmodics Inc- for 2017, company now expects gaap revenue to range from $64.0 million to $68.0 million, up from a previous range of $63.0 million to $67.0 million . Surmodics Inc - company now expects diluted earnings in range of loss per share of $0.07 to earnings of $0.08 per share for 2017 . Surmodics Inc sees non-GAAP earnings of $0.18 to $0.33 per share for 2017 .FY2017 earnings per share view $0.24, revenue view $65.3 million -- Thomson Reuters I/B/E/S.  Full Article

Surmodics reports Q3 non-gaap EPS $0.37
Thursday, 28 Jul 2016 07:30am EDT 

Surmodics Inc : Surmodics reports third quarter fiscal 2016 results . Raises FY 2016 non-gaap earnings per share view to $0.98 to $1.08 . Q3 gaap earnings per share $0.30 from continuing operations . Q3 revenue $20 million versus I/B/E/S view $16.3 million . Raises fy 2016 gaap earnings per share view to $0.52 to $0.59 . Sees fy 2016 revenue $68 million to $70 million . Q3 earnings per share view $0.12 -- Thomson Reuters I/B/E/S .FY2016 earnings per share view $0.78, revenue view $65.7 million -- Thomson Reuters I/B/E/S.  Full Article

SurModics Inc reaffirms FY 2016 guidance
Thursday, 28 Jan 2016 07:35am EST 

SurModics Inc:Says it is reaffirming its previously stated guidance for FY 2016.Expects revenue to range from $62 million to $66 million, with diluted GAAP earnings in range of $0.30 to $0.35 per share and non-GAAP earnings of $0.66 to $0.75 per share.  Full Article

SurModics Inc acquires NorMedix
Monday, 11 Jan 2016 08:00am EST 

SurModics Inc:Acquires Normedix, a design and development company focused on minimally invasive catheter technologies.Says Surmodics acquired normedix for $14 million, including an upfront payment of $7 million.Says other financial terms of the agreement were not disclosed.Says Surmodics is adjusting fiscal 2016 revenue guidance.Sees 2016 revenue $62 million to $66 million.Sees FY 2016 revenue guidance from a range of $60 million to $64 million to an adjusted range of $62 million to $66 million.  Full Article

SurModics Inc acquires Creagh Medical Ltd
Friday, 20 Nov 2015 08:00am EST 

SurModics Inc:Acquires Creagh Medical Ltd.Says deal valued at $32 million.Says deal to be accretive on an adjusted earnings per share basis in fiscal year 2017.Says creagh medical business is expected to generate $3.5 million to $4 million of revenue for Surmodics in fiscal year 2016.Says acquisition will be dilutive on a GAAP and adjusted earnings per share basis in surmodics' fiscal year 2016.  Full Article

SurModics Inc receives FDA ide approval
Monday, 5 Oct 2015 08:00am EDT 

SurModics Inc:Receives FDA ide approval for early feasibility study of the Surveil(TM) drug-coated balloon.Says expects to enroll the first patient in the second quarter of fiscal 2016.  Full Article

SurModics Inc raises low end of prior FY 2015 revenue guidance to a range in line with analysts' estimates; raises FY 2015 EPS guidance
Wednesday, 5 Aug 2015 07:30am EDT 

SurModics Inc:Expects FY 2015 revenue to be in the range of $58.0 million to $60.0 million, an increase from the previous range of $57.0 million to $60.0 million.Expects FY 2015 diluted GAAP earnings to be in the range of $0.95 per share to $1.00 per share, up from the previous range of $0.85 per share to $0.95 per share (EPS).FY 2015 revenue of $58.7 million and EPS of $0.89 - Thomson Reuters I/B/E/S.  Full Article

SurModics Inc reaffirms FY 2015 guidance - conference call
Wednesday, 3 Jun 2015 08:30am EDT 

SurModics Inc:Expects FY 2015 revenue to be in the range of $57-$60 million.Expects FY 2015 EPS to be in the range of $0.85-$0.95.  Full Article

More From Around the Web

BRIEF-Surmodics amends and restates its secured revolving credit facility

* On November 2 amended and restated its secured revolving credit facility pursuant to an amended and restated credit agreement